Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Olaf Stüve Clear advanced filters

  • A recent multicentre study has assessed the risk of relapse in patients with multiple sclerosis who switched from natalizumab to fingolimod treatment. Despite such efforts, no effective exit strategy from natalizumab treatment has yet been demonstrated for these patients.

    • Martin Stangel
    • Olaf Stüve
    News & Views
    Nature Reviews Neurology
    Volume: 10, P: 311-313

  • A number of established therapies are available for multiple sclerosis (MS), but the advent of numerous novel therapies has meant that treatment decisions for MS are becoming increasingly complex. In this Review, Kieseier and Stüve discuss the challenges that both neurologists and patients face in terms of treatment decision-making, and highlight the risks, benefits and treatment paradigms associated with MS therapy.

    • Bernd C. Kieseier
    • Olaf Stüve
    Reviews
    Nature Reviews Neurology
    Volume: 7, P: 255-262

  • Combination therapy is a rational strategy to optimize therapeutic benefits and minimize risks associated with treatment of patients with multiple sclerosis (MS). A recent study reporting negative results of combination therapy in MS should not discourage investigators from future attempts to identify optimal combinations for the treatment of this disease.

    • Bernd C. Kieseier
    • Olaf Stüve
    News & Views
    Nature Reviews Neurology
    Volume: 7, P: 659-660

  • Cerebrospinal fluid (CSF) investigation should be routinely performed in patients with a first clinical event that is suggestive of multiple sclerosis (MS). This Review highlights the value of existing CSF biomarkers in eliminating potential differential diagnoses for MS and understanding the underlying pathophysiology of this condition. The authors also discuss the potential for novel biomarkers that could be used in prognosis.

    • Martin Stangel
    • Sten Fredrikson
    • Hayrettin Tumani
    Reviews
    Nature Reviews Neurology
    Volume: 9, P: 267-276

  • The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.

    • Navid Manouchehri
    • Olaf Stüve
    Comments & Opinion
    Nature Reviews Neurology
    Volume: 15, P: 431-432